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SDF-1 expression after preoperative chemoradiotherapy is 
associated with prognosis in patients with advanced lower 
rectal cancer
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Abstract : Stromal cell-derived factor-1 (SDF-1) expression is associated with cancer progression, as a biomarker 
of prognosis. We clarified the significance of SDF-1 expression on chemoradiotherapy (CRT) resistance and prog-
nosis in advanced lower rectal cancer patients. We evaluated 98 patients with advanced lower rectal cancer who 
underwent preoperative CRT. All patients received 40 Gy of radiation therapy, with concurrent chemotherapy 
containing fluorinated pyrimidines, followed by surgical resection. SDF-1 expression in surgical specimens was 
examined by immunohistochemistry. We divided the patients into SDF-1-positive- (n = 52) and SDF-1-negative 
groups (n = 46) and compared the clinicopathological factors and survival rates. The SDF-1-positive group was 
more resistant to CRT than the SDF-1-negative group (non-responder rate, 63.5% vs. 47.8%, respectively ; p = 0.12). 
Overall survival (OS) in the SDF-1 positive group was significantly poorer vs. the SDF-1-negative group (5-year 
OS, 73.4% vs. 88.0%, respectively ; p = 0.02), and disease-free survival (DFS) was worse (5-year DFS, 61.0% vs. 74.1%, 
respectively ; p = 0.07). Multivariate analysis confirmed that SDF-1 expression was a significant independent 
prognostic predictor of OS (p = 0.04). SDF-1 expression after preoperative CRT is significantly associated with a 
poor prognosis in advanced lower rectal cancer patients and is a promising biomarker. J. Med. Invest. 68 : 309-
314, August, 2021
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INTRODUCTION
 
Preoperative chemoradiotherapy (CRT) is widely used as a 
major treatment modality in advanced lower rectal cancer pa-
tients to control local tumor progression, allow sphincter-sparing 
surgery, and improve survival (1, 2). However, the rate of distant 
metastasis after CRT followed by radical operation in advanced 
lower rectal cancer patients remains high at 15%–20% (2-4). 
New biomarkers are necessary to select patients with a high risk 
of recurrence and allow for personalized therapy.
Stromal cell-derived factor-1 (SDF-1) is a CXC chemokine and 
is also known as CXC motif chemokine ligand-12 (CXCL12). 
SDF-1 is ubiquitously expressed in almost all organs, and is es-
sential for hematopoiesis, vascular development, cardiogenesis, 
and neurogenesis (5-7). CXC chemokine receptor-4 (CXCR4), 
which is an SDF-1 receptor, expresses on the cell surface of 
hematopoietic stem cells and T and B lymphocytes, and SDF-1 
is implicated in the homing of these cells (8, 9). CXCR4 also 
express on the surfaces of malignant cells ; the SDF-1 / CXCR4 
axis enhances cancer cell survival, proliferation, angiogenesis, 
and metastasis (10, 11). In addition, high expression of SDF-1 in 
cancer cells attracts CXCR4-positive cells, such as cancer-asso-
ciated fibroblasts (CAF) or immune cells, including myeloid-de-
rived suppressor cells (MDSC), regulatory T cells (Treg) and 
tumor-associated macrophages (TAM), to the tumor sites and 
converts the tumor microenvironment (TME) to immune tol-
erance (12-14). Therefore, SDF-1 might have potential as a new 
therapeutic target, and could be a useful biomarker for patients 
with malignant tumors.
SDF-1 expression in cancer cells promotes the progression of 
breast cancer, lung cancer, and lymphoma, and could be a bio-
marker for a poor prognosis (15-17). The significance of SDF-1 
expression remains unclear, and few reports have focused on 
SDF-1 expression in advanced lower rectal cancer (18, 19). Re-
cently, several reports described that SDF-1 was a factor related 
to resistance to radiotherapy for glioblastoma, and head and 
neck cancer (20, 21). In this study, we evaluated whether SDF-1 
expression in cancer cells could induce radiation resistance and 
lead to a poor prognosis in advanced lower rectal cancer patients 
undergoing preoperative CRT.
The aim of this study was to investigate the significance of 
SDF-1 expression in advanced lower rectal cancer patients un-
dergoing preoperative CRT. 
PATIENTS AND METHODS
Patients
We evaluated 98 surgically-resected specimens from advanced 
lower rectal cancer patients who underwent preoperative CRT 
followed by radical resection from April 2006 to July 2018 at 
Tokushima University Hospital. The indications for preoperative 
CRT at our institution were previously reported (22). Briefly, 
preoperative CRT was offered to advanced lower rectal cancer 
patients who were diagnosed with locally advanced (≥ T3 and / or 
≥ N1) cancer or to those who were estimated to have T2 cancer 
close to or involving the anal sphincter. Preoperative pelvic 
irradiation constituted a total dose of 4000 cGy at 200 cGy per 
fraction daily, five times weekly. The radiation field included 
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the lateral pelvic lymph nodes, and radiation therapy was ad-
ministered concomitantly with chemotherapy that included 
fluorinated pyrimidines. The regimen constituted tegafur-uracil 
(UFT) or S-1 orally, only (n = 18, n = 45, respectively) ; S-1 and 
oxaliplatin ; bevacizumab (SOX + Bev, n = 33) ; or S-1 and CPT-
11 (IRIS, n = 2).
This study was approved by the Institutional Review Board of 
Tokushima University (Tocms2901-1). This study was conduct-
ed according to the principles expressed in the Declaration of 
Helsinki. All tissue samples included in this investigation were 
obtained with the patients’ informed consent. 
Immunohistochemical staining
The immunohistochemical method was reported previously 
(22). Briefly, paraffin sections were cut at 4-μm thicknesses from 
archival formalin-fixed paraffin-embedded tissue blocks. The 
sections were deparaffinized using xylene and dehydrated using 
a series of graded ethanol solutions. Endogenous peroxidase 
activity was blocked by administering 0.3% hydrogen peroxidase 
and methanol. After washing three times for 5 minutes (each 
wash) with phosphate-buffered saline (PBS), the sections were 
processed in 10 mM EDTA buffer (pH : 9) in a microwave for an-
tigen retrieval. After cooling at room temperature, the sections 
were incubated with primary mouse monoclonal antibody for 
SDF-1 (MAB350, dilution 1 : 50 ; R&D Systems, Minneapolis, 
MN, USA) at 4℃, overnight, followed by three washes. The 
sections were then incubated with a Dako REAL EnVision / HRP 
detection system (Dako, Tokyo, Japan) for 1 hour. After three 
washes, 3,3′-diaminobenzidine tetrahydrochloride (DAB) was 
used to develop the peroxidase reaction. Nuclei were counter-
stained with Mayer’s hematoxylin solution to complete the 
procedure.
SDF-1 expression in cancer cells was scored by staining 
intensity (SI), as follows : no staining = 0 ; weak = 1 ; moder-
ate = 2 ; and strong = 3 (23). We then categorized SDF-1 values 
into negative and positive groups (0, 1 : SDF-1-negative ; 2, 
3 : SDF-1-positive).
Pathological evaluation 
Evaluation of patients’ therapeutic responses to preoperative 
CRT was described previously (24). Briefly, the evaluation of 
surgical specimens was performed according to the histopatho-
logical response criteria of the general rules for clinical and 
pathological studies on cancer of the colon, rectum, and anus 
(Japanese Classification of Colorectal, Appendiceal, and Anal 
Carcinoma). All specimens with SDF-1-positive grade 2 or 3 were 
classified as responders, and specimens with grade 0 or 1 were 
classified as non-responders.
Statistical analyses
All statistical analyses were performed using JMP statistical 
software (version 8.0.1 ; SAS Institute Inc., Cary, NC, USA). 
The χ2-test and Mann–Whitney U test were used to compare 
the clinicopathological variables between the two groups. Sur-
vival curves were created using the Kaplan–Meier method, and 
the curves were compared using the log-rank test. p < 0.05 was 
considered statistically significant.
RESULTS
Typical immunohistochemistry images of SDF-1-positive 
cells in lower rectal cancer tissues are shown in Figure 1. All 
patients were divided into an SDF-1-positive group (n = 52) or 
-negative group (n = 46). The clinicopathological characteristics 
of each group are shown in Table 1. SDF-1 expression correlated 
Figure 1.　Representative immunohistochemical staining of stromal 
cell-derived factor-1 (SDF-1).
SDF-1 expression was assessed in the cytoplasm of cancer cells.
Table 1.　Comparison of the clinicopathological characteristics between  the SDF-1-positive and -negative groups
Variable SDF-1-negative (n=46) SDF-1-positive (n=52) p-value
Age (years) 63 ± 10 66 ± 9 0.11
Sex (M / F) 30 / 16 35 / 17 0.82
Location (Ra / Rb / P) 8 / 37 / 1 7 / 42 / 3 0.58
Depth of invasion (T1–2 / T3–4) 24 / 22 21 / 31 0.24
Lymph node metastasis (− / +) 38 / 8 34 / 18 0.05
Lymphatic invasion (− / +) 30 / 9 29 / 18 0.12
Venous invasion (− / +) 20 / 19 24 / 24 0.90
Differentiation (tub1 / tub2 / others) 22 / 22 / 2 20 / 29 / 3 0.47
Stage (0 / I / II / IIIa / IIIb / IV) 6 / 18 / 11 / 5 / 4 / 2 5 / 12 / 16 / 6 / 9 / 4 0.46
Neoadjuvant chemotherapy 
(UFT / S-1 / IRIS / SOX+Bev) 10 / 26 / 0 / 10 8 / 19 / 2 / 23 0.02
Adjuvant chemotherapy (− / +) 40 / 6 39 / 13 0.13
SDF-1, stromal cell-derived factor-1 ; y, years ; M, male ; F, female ; Ra, rectum above the peritoneal reflection ; Rb, rectum 
below the peritoneal reflection ; P, proctos ; tub1, well differentiated adenocarcinoma ; tub2, moderately differentiated ade-
nocarcinoma ; UFT, uracil / tegafur ; IRIS, irinotecan plus S-1 ; SOX, S-1 combined with oxaliplatin ; Bev, bevacizumab
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with lymph node metastasis and neoadjuvant chemotherapy 
regimens. We investigated whether there was a correlation 
between SDF-1 expression and the effect of radiation therapy. 
Approximately 63.5% of the patients in the SDF-1-positive group 
and 47.8% in the SDF-1-negative were non-responders to preop-
erative CRT (p = 0.12, Fig. 2).
Overall survival (OS) in the SDF-1-positive group was sig-
nificantly poorer than that in the SDF-1-negative group (5-
year OS, 74.3% vs. 88.0%, respectively ; p < 0.05 ; Fig. 3A), 
and disease-free survival (DFS) was also poorer (5-year DFS, 
61.0% vs. 74.1%, respectively ; p = 0.07 ; Fig. 3B). Univariate 
analysis showed that sex, pT, pN, lymphatic invasion, serum 
CEA concentration, and SDF-1-positive expression were sig-
nificant prognostic factors for OS, and pT, pN, lymphatic inva-
sion, and high expression of SDF-1 were prognostic factors for 
DFS (Table 2 and Table 3). Multivariate analysis showed that 
SDF-1 was a significant independent risk factor for both OS 
(relative risk, 2.85 ; p = 0.04 ; Table 2) and DFS (relative risk, 
2.07 ; p = 0.06 ; Table 3).
 
Figure 2.　Pathological response to preoperative CRT after surgical 
resection
The Stromal cell-derived factor-1 (SDF-1)-positive group had more 
non-responders compared with the SDF-1-negative group.
Figure 3.　Kaplan–Meier analysis of overall survival (A) and disease-free survival (B) for stromal cell-derived factor-1 
(SDF-1) expression.
A B
Table 2.　Univariate and multivariate analysis of the prognostic factors for overall survival (OS)
Variable 5-year OS (%)
Univariate Multivariate
p-value HR (95% CI) p-value
Age (< 60 / ≥ 60 years) 87.5 / 78.7 0.51 0.84 (0.25–2.82) 0.77
Sex (M / F) 81.4 / 79.1 0.70 1.15 (0.40–3.24) 0.78
Tumor differentiation (tub1, tub2 / others) 80.9 / 80.0 0.92 0.79 (0.09–6.82) 0.83
T stage (T1–2 / T3–4) 87.0 / 75.5 0.02 1.40 (0.45–4.32) 0.55
Lymph node metastasis  (− / +) 88.1 / 58.8 < 0.01 2.09 (0.54–8.09) 0.28
Lymphatic invasion  (− / +) 88.6 / 57.3 < 0.01 3.04 (0.94–9.81) 0.06
Venous invasion  (− / +) 84.1 / 71.6 0.17 2.41 (0.84–6.91) 0.10
CEA (< 5 ng / ml / ≥ 5 ng / ml ) 81.3 / 71.4 0.01 4.53 (1.14–17.93) 0.03
Adjuvant chemotherapy (− / +) 83.0 / 71.2 0.19 3.27 (0.81–1.14) 0.08
SDF-1 (negative / positive) 88.0 / 74.3 0.02 2.85 (1.00–8.11) 0.04
HR, hazard ratio ; CI, confidence interval ; y, years ; M, male ; F, female ; tub1, well differentiated adenocarcinoma ; tub2, 
moderately differentiated adenocarcinoma ; CEA, carcinoembryonic antigen ; SDF-1, stromal cell-derived factor-1
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DISCUSSION
In the current study, we identified the significance of SDF-1 
expression as a biomarker for predicting the prognosis of ad-
vanced lower rectal cancer patients undergoing preoperative 
CRT, using immunohistochemical staining. 
SDF-1 activates the downstream signal pathways, such as 
PI3K / AKT / mTOR and ERK1 / 2, and enhances cancer cell sur-
vival, proliferation, and chemotaxis by binding to CXCR4 (25). 
High SDF-1 expression was associated with a poor prognosis in 
esophagogastric, pancreatic, and lung cancer patients in two me-
ta-analyses (26, 27). In CRC patients, the significance of SDF-1 
expression in cancer cells remains controversial because SDF-1 
is reported to be both tumor promoting (28) and tumor suppres-
sive (29). There are only a few reports of the significance of SDF-1 
expression in cancer cells regarding prognosis in advanced lower 
rectal cancer patients (18, 19). In cancer cells, the SDF-1 / CXCR4 
axis activates intracellular signaling through the MEK / ERK 
and PI3K / AKT pathways and promotes cell survival and prolif-
eration, and metastasis (30, 31). In addition, SDF-1 can attract 
CXCR4-positive cells, such as CAF, MDSC, Treg, or TAM, to 
the tumor sites and assist tumor progression in the TME (10, 
14). Our data showed that SDF-1 expression in cancer cells after 
preoperative CRT was an independent prognostic factor for OS 
in advanced lower rectal cancer patients. Our data also showed 
that SDF-1 expression correlated with higher recurrence rates. 
Our results were compatible with previous reports, and indicate 
the significance of SDF-1 in advanced lower rectal cancer pa-
tients undergoing preoperative CRT.
Several researchers reported that SDF-1 expression induced 
resistance to radiation therapy in glioblastoma, and head and 
neck cancer (20, 21). Kim et al. reported that upregulation of 
SDF-1 before and after preoperative CRT was associated with 
radiation resistance (18). In our study, SDF-1 expression in can-
cer cells correlated with response to radiotherapy. To the best of 
our knowledge, no previous reports identified the mechanism of 
acquiring radiation resistance via upregulation of SDF-1 expres-
sion in advanced lower rectal cancer. Recently, converting the 
TME has been shown to be an important factor inducing radia-
tion resistance in cancer cells (32-34), and several studies showed 
that MDSC and Treg recruitment to the TME was a major factor 
in radiation resistance (35, 36). As the SDF-1 / CXCR4 axis plays 
a crucial role in recruiting MDSCs and Tregs to the TME (37, 
38), we speculate that upregulation of SDF-1 expression may in-
duce tumor radiation resistance via infiltration of these immune 
cells. In a future study, we will investigate the relationship be-
tween SDF-1 expression in tumors and immune cell infiltration.
Increasing experimental evidence suggests using the 
SDF-1 / CXCR4 axis as a therapeutic target. Some researchers 
showed that inhibiting the SDF-1 / CXCR4 axis improved tumor 
malignancy and survival. For example, AMD3100, an an-
ti-CXCR4 drug, was associated with reduced proliferation and 
metastasis of cancer cells in ovarian cancer (39), and NOX-A12, 
an anti-SDF-1 aptamer, improved the survival of irradiated rats 
with glioblastoma (40). Other researchers have also suggested 
that modulating the SDF-1 / CXCR4 axis could revert the tolero-
genic polarization of the TME, and modulate immunotherapy 
with anti-CTLA-4 or anti–PD-1 antibody (13, 41). 
There are limitations in our study. While almost 100 tissue 
specimens were included in the analysis, sample sizes were rela-
tively small. However, SDF-1 expression correlated with CRT re-
sponse. To further investigate the relationship between radiation 
resistance and SDF-1 expression, it will be necessary to evaluate 
not only the SDF-1 expression level after surgical resection, but 
also the SDF-1 expression level prior to preoperative CRT.
In conclusion, in advanced lower rectal cancer, cancer cells 
expressing SDF-1 were less sensitive to radiation therapy and 
more frequently associated with postoperative recurrence. Addi-
tionally, SDF-1 expression was an independent prognostic factor 
for OS. SDF-1 expression in cancer cells is a useful biomarker 
and has the potential to become a new therapeutic target.
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Table 3.　Univariate and multivariate analysis of the prognostic factors for disease-free survival (DFS)
Variable 5-year DFS (%)
Univariate Multivariate
p-value HR (95% CI) p-value
Age (< 60 y / ≥ 60 y) 79.1 / 63.7 0.31 1.34 (0.51–3.54) 0.54
Sex (M / F) 67.9 / 66.3 0.79 0.58 (0.26–1.27) 0.17
Tumor differentiation (tub1, tub2 / others) 67.8 / 60.0 0.73 0.76 (0.16–3.65) 0.73
T stage (T1–2 / T3–4) 84.1 / 53.5 < 0.01 1.61 (0.59–4.34) 0.34
Lymph node metastasis (− / +) 76.9 / 42.3 < 0.01 3.02 (1.03–8.40) 0.04
Lymphatic invasion (− / +) 74.8 / 36.6 < 0.01 3.11 (1.34–7.19) < 0.01
Venous invasion (− / +) 70.3 / 55.1 0.11 1.61 (0.70–3.71) 0.25
CEA (< 5 ng / ml / ≥ 5 ng / ml ) 69.0 / 42.8 0.09 2.87 (0.82–10.06) 0.09
Adjuvant chemotherapy (− / +) 71.2 / 52.6 0.06 2.63 (0.13–1.05) 0.06
SDF-1 (negative / positive) 74.1 / 61.0 0.07 2.07 (0.94–4.55) 0.06
HR, hazard ratio ; CI, confidence interval ; y, years ; M, male ; F, female ; tub1, well differentiated adenocarcinoma ; tub2, 
moderately differentiated adenocarcinoma ; CEA, carcinoembryonic antigen ; SDF-1, stromal cell-derived factor-1
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